MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Drug: epoetin alfa or beta
First Posted Date
2004-04-16
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
336
Registration Number
NCT00081484

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

Phase 3
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2004-03-17
Last Posted Date
2016-06-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1987
Registration Number
NCT00009737

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2004-02-16
Last Posted Date
2013-05-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
470
Registration Number
NCT00077857

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Drug: Darbepoetin alfa
First Posted Date
2004-02-16
Last Posted Date
2016-10-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
313
Registration Number
NCT00077766

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Phase 4
Completed
Conditions
Hepatitis C, Chronic
Interventions
Drug: ribavirin [Copegus]
Drug: peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
First Posted Date
2004-02-13
Last Posted Date
2016-04-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
188
Registration Number
NCT00077649

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: RO0503821 (1x/2 Weeks)
Drug: RO0503821 (1x/4 Weeks)
Drug: Epoetin alfa or beta
First Posted Date
2004-02-13
Last Posted Date
2017-01-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
673
Registration Number
NCT00077610

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
Drug: epoetin alfa or beta
First Posted Date
2004-02-13
Last Posted Date
2016-05-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
572
Registration Number
NCT00077623

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Phase 4
Completed
Conditions
Hepatitis C, Chronic
Interventions
Drug: Copegus
Drug: peginterferon alfa-2a [Pegasys]
First Posted Date
2004-02-13
Last Posted Date
2016-02-23
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1469
Registration Number
NCT00077636

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Drug: epoetin
First Posted Date
2004-02-12
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
182
Registration Number
NCT00077597

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Phase 3
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2003-09-18
Last Posted Date
2020-03-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1886
Registration Number
NCT00069121
Locations
🇺🇸

New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States

🇺🇸

Innovative clinical research institute/American institute of research, Whittier, California, United States

🇺🇸

Nh Oncology Hematology, Pa, Hooksett, New Hampshire, United States

and more 229 locations
© Copyright 2025. All Rights Reserved by MedPath